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Background: Multimorbidity is defined as suffering from coexistent chronic conditions. Multimorbid patients
demand highly complex patient-centered care which often includes polypharmacy, taking an average of six
different drugs per day. Adverse drug reactions, adverse drug events and medication errors are all potential
consequences of polypharmacy. Our study aims to detect the status quo of the health care situation in Saxony’s
general practices for multimorbid patients receiving multiple medications. We will identify the most common
clinical profiles as well as documented adverse drug events and reactions that occur during the treatment of
patients receiving multiple medications. We will focus on exploring the motives of general practitioners for the
prescription of selected drugs in individual cases where there is evidence of potential drug-drug-interactions and
potentially inappropriate medications in elderly patients. Furthermore, the study will explore general practitioners’
opinions on delegation of skills to other health professions to support medical care and monitoring of patients
receiving multiple medications.
Methods/design: This is a retrospective cross sectional study using mixed methods. Socio-demographic data as
well as diagnoses, medication regimens and clinically important events will be analyzed retrospectively using
general practitioners documentation in patients’ records. Based on these data, short vignettes will be generated
and discussed by general practitioners in qualitative telephone interviews.
Discussion: To be able to improve outpatient health care management for patients receiving multiple medications,
the current status quo of care, risk factors for deficient treatment and characteristics of concerned patients must be
investigated. Furthermore, it is necessary to understand the physicians’ decision making process regarding treatment.
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Patient age is correlated with the probability of having
coexistent chronic conditions, known as multimorbidity,
which requires highly complex patient-centered care [1].
Although there is no generally accepted definition of
multimorbidity, it is obvious that the coexistence of sev-
eral chronic diseases often affects patients’ quality of life.
Furthermore, communities are confronted with socio-
economic and medical challenges concerning the whole
health care sector [2]. Health care expenditures are cor-
related with the intensive care of patients within the last* Correspondence: Mandy.Gottschall@uniklinikum-dresden.de
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reproduction in any medium, provided the orsix months of life, over-medication and polypharmacy
[3,4]. Regarding this, medication management could re-
duce health care expenditures [5-8].
In their literature review, Fortin et al. analyzed
multimorbidity prevalences between 49 and 99% for in-
dividuals older than 65 years, living in the USA [9-11],
Netherlands [12,13], Israel [14] and Canada (Québec)
[15]. For these purposes, multimorbidity was defined as
the existence of two or more chronic diseases [16]. For
Germany there are only a few population-based studies
concerning the prevalence of multimorbidity [17-19]. In
2011, van den Bussche et al. published a study based on
health insurance data showing that 62% of 120,000 in-
sured individuals over the age of 65 had more than three
chronic diseases [20]. The Department of General Prac-
tice of the Dresden University of Technology conductedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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62% of 2,529 Saxon patients treated by a general practi-
tioner (GP) suffered from multimorbidity (again defined
as having two or more documented chronic conditions
[21]). The CONTENT-Project (CONTinuous morbidity
registration Epidemiologic NeTwork) of the University
of Heidelberg offered data from more than 30,000 pa-
tients who were treated by GPs. The patients were
predominantly from a western region of Germany (Baden-
Württemberg) and confirmed a positive correlation be-
tween their age and the number of chronic diseases.
Furthermore the investigation showed that the number
of chronic diseases has a significant influence on the
number of medications taken [22].
Overall, 20% of GPs’ patients over 65 receive 60% of
all prescribed drugs [23]. Consequently, polypharmacy is
one important aspect that should be considered in the
management of multimorbid patients. In a national
survey Kaufman et al. found that 57% of women over 65
living in the United States take more than five prescrip-
tion medications [24]. A European study showed that
51% of participating patients take more than six pres-
cribed medications per day [25]. Scientists from the
German PRISCUS-Network observed that those patients
take on average six different drugs per day. The number
of drugs was significantly higher in patients over 65.
The PRISCUS-Network consists of institutes, hospitals
and groups working in health care, is promoted by the
Federal Ministry of Education and Research, and focuses
on investigating issues concerning the drug regimen on
multimorbid elderly [26].
An analysis of the pharmacotherapy and medicine con-
sulting service for physicians by the Association of Statu-
tory Health Insurance Physicians in Saxony showed that
patients take on average 4.7 drugs simultaneously [27]; in-
dividual patients were shown to take up to 21 drugs. In the
framework of the federal government’s health monitoring it
is pointed out that an individual should not take more than
four drugs regularly [28]. Already five active ingredients
that cause drug interactions are unclear and unpredictable
[29,30], but regarding, for instance, cardiovascular diseases,
the prescription of different active ingredients is clinically
necessary and explains polypharmacy rates of 40% (includ-
ing over-the-counter drugs) in patients over 75 [31].
In addition to potential adverse drug reactions (ADR)
including interactions and adverse reactions, adverse
drug events (ADE) and medication errors are further
risks or rather potential consequences of polypharmacy
[32-34]. ADE appear in approximately 13% of medica-
mentous and out-patient treated individuals and cause -
besides individual health effects - a high economic burden
[35], which is estimated at 800 million Euros per year
for Germany [36]. Older people are particularly affected
by ADE, as multimorbidity is associated with age [37].Medication or dosage errors as well as non-compliance
occur far more frequently and result from unclear dosage
and medication instructions or complex disease manage-
ment [38]. Moreover, self-medication means that physi-
cians have a limited overview and control of adequate
medication management. In Germany and in a large num-
ber of other European countries, the GP usually manages
the whole treatment including medication management of
multimorbid patients.
Based on polypharmacy and age-related pharmacoki-
netic and pharmacodynamic changes, the risk of ADR
and ADE is increasing in elderly patients [39]. There
are several drugs for elderly patients for which the
risks of intake outweigh the benefits, known as po-
tential inappropriate medications (PIM). Building on
this, a few lists with recommendations or guidelines
for managing appropriate medication in elderly has
been developed, such as the Beers criteria [40] or the
STOPP criteria [41].
As potential inappropriate medication and prescriptions
occur frequently among the elderly in Germany, a
PRISCUS-Network study was performed. Eighty three
potentially inappropriate drugs for elderly typical in the
German drug market were identified and summarized in
the PRISCUS-list [23]. Due to the complex pharmaco-
therapy of geriatric patients, such instruments may sup-
port patient-centered care with the aim of avoiding
inappropriate medication. Therefore listed drugs are in-
creasingly integrated in guidelines. Although using the
PRISCUS-list can improve the medical care of the elderly
it has still some deficiencies. The list includes advice
concerning comorbidities but it does not focus on
multimorbidity or polypharmacy [23]. Further projects fo-
cusing on improving the treatment of multimorbid pa-
tients in Germany are predominantly done in the context
of trans-sectoral cooperation [42-44]. Preliminary results
show that through this cooperation, physicians are able to
detect inadequate medication and potential ADE early
within the treatment process, reduce adverse events and
improve patients’ knowledge as well as behavior.
Against this background we will conduct a study that
focuses on polypharmacy in multimorbid patients in
GPs’ practices. We intend to determine the status quo of
medication of multimorbid patients as well as different
patterns of polypharmacy in general practices in Saxony.
Furthermore, we want to explore motives for GPs’ med-
ical prescription in case of prescription of potentially in-
appropriate medication. We aim to create scientific
evidence that helps to develop a sustainable and region-
specific care management. Compared to other German
federal states, Saxony has the highest percentage of pa-
tients over 65 (24.7%) [45]. By 2020, the number of pa-
tients over 65 is expected to rise to 28.5%. Hence, in
Germany one of the oldest population currently and in
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Figure 1 Study procedure.
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strategic solutions, Saxony could play a leading role for
the other German federal states. Recent study results in
the field of pharmacoepidemiology could identify re-
gional differences in care, especially concerning medica-
tion [46-48]. In addition, the current German social law
requires that patient-centered care should be improved by
making it more regionally oriented and flexible [49].
Therefore, the study aims to detect the status quo of the
health care situation in GPs’ practices for multimorbid
patients receiving multiple medications in Saxony. In
addition to the criteria of polypharmacy and multi-
morbidity we will also identify the most common clinical
profiles and related ADE and ADR documented by the par-
ticipating GPs (for example risk of falling, delirium and
syncope). We aim to identify demands, obstacles and op-
portunities for improvement.
Summarized, the study will focus on following research
questions:
(1) What is the current situation of health care in GPs’
practices concerning multimorbid patients receiving
polypharmacy?
(2) Which problems appear during the treatment of
patients receiving polypharmacy?
(3) What are the motives for GPs’ decision making
regarding prescription of potentially inappropriate
drugs?
(4) Which patient groups should be differentiated from
GPs’ point of view, to address specific treatment
processes correctly?
(5) May the delegation of medical work in GPs’
practices to other health professionals improve the
care of multimorbid patients receiving multiple
medications and what should be delegated to whom?
Based on this explorative study, hypotheses for re-
gional concepts of patient-centered care under consider-
ation of polypharmacy will be generated and should be
tested in further studies.
Methods
Study design
This retrospective cross sectional study using mixed
methods consists of three different research parts (Figure 1):
(1) Content analysis of patient records
(2) Interview with GPs including short vignettes that
focus on prescription of PIM and polypharmacy
(3) Interview with medical assistants
Ethics approval for the study was obtained from the
Ethics Commission of the Medical Clinic, Dresden Uni-
versity of Technology. Approval number: EK410122012.Setting
The study will be conducted in the setting of outpatient
primary care in the urban region of Dresden. The academic
teaching practices from the Department of General Practice
of the Dresden University of Technology in Saxony will be
invited for recruitment of GPs, medical assistants and
patients.
Recruitment of study participants
GPs from academic teaching practices (n ≈ 40) will be
asked to participate. Considering the experience of pre-
vious research with academic teaching practices, we
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contacted by an informative letter briefly explaining de-
tails of required data and the interview process. After
written confirmation of participation in the study by in-
terested GPs, a project assistant will visit the participat-
ing GPs personally to explain study design, provide
study instruction and gain the GPs’ agreement to par-
ticipate. In this context, a monetary incentive will be
provided to positively influence participation and co-
operation [51-53].
Patients will be recruited by a project assistant with
support from the medical assistants and the GPs by
screening patients’ records for the accounting code for
patients with chronic diseases. This accounting code is
defined by at least two consultations at GPs practice per
quarter and at least one chronic disease for more than a
year, which requires regular treatment. Based on this list
of chronic patients, every patient will be checked for the
following inclusion criteria: a) at least two parallel
chronic diseases and b) two prescribed long-term medi-
cations at least six months before 2012. The invitation
to participate in the study will contain a personal cover
letter from the GP, information about the research study,
the declaration of consent and a prepaid envelope for
responding and will be dispatched by postal service to
the included patients. Patients that send back their con-
sent will be included for analysis. In case of incapaci-
tated patients (such as demented persons), approval by
custodians could be given.
Based on a prevalence of about 60% of multimorbid
patients in general practice [20,21], we plan to include of
200 patients per practice. Thereby, the total sample re-
sults in approximately 2000 patients (10 practices, each
with 200 patients).
Research instruments
For the collection of data following instruments will be
used:
(1) Semi-standardized content analysis (pseudonymous)
of patient’s records using prepared analytical
protocols
(2) Standardized questionnaire describing participating
GPs and practices
(3) PRISCUS-list to compare the prescribed drugs for
elderly patients
(4) Semi-standardized and guideline-based single
telephone interviews with GP
(5) Semi-standardized and guideline-based single face-to-
face interviews with medical assistants/receptionists
Semi-standardized instruments will be used to collect
comparable data as well as to ensure openness toward
unpredictable information.Research instruments, strategies for recruitment of
participants and data collection were tested within a pre-
test that was conducted by one of the co-operation part-
ners with a GP practice in Wuppertal in February/
March 2013.
(1) Content analysis (pseudonymous) of patient’s records
Patient records will be retrospectively analyzed per
patient and per quarter in 2012. The quarters will
be assigned randomly to the patients. The analysis
will be focused on a) determination of morbidity
profiles, participation in chronic care programs and
acute diseases, b) associated drug prescriptions, c)
admission and referral to specialists and other
health professionals, d) patients’ socio-demographic
data and number of consultations in GPs’ practice.
(2) Standardized questionnaire describing participating
GPs and practices
We will collect information on characteristics of the
participating practices, for example type of practice,
number of patients per quarter, age and duration of
professional experience, delegation to medical
assistants, proportion of elderly patients ≥ 65 years
and experience with the PRISCUS-list.
(3) PRISCUS-list to compare the prescribed drugs for
elderly patients
We will compare the prescribed drugs with the
PRISCUS-list to identify potentially inappropriate
medication. Furthermore, we will explore examples
for generating short vignettes that will be discussed
in the interviews with GPs.
(4) Semi-standardized and guideline-based single
telephone interviews with GP
GPs will be interviewed to discuss the results of the
patient`s records analysis and to understand their
decision making in treatment of multimorbid
patients. Thereby, the reasons for an exceptional
prescription of a medication of the PRISCUS-list
will be explored. Furthermore, it will be explored
whether the GPs ask their patients regularly about
self-medication, co-treating physicians or ADE. It is
also important to determine if the patients receive
any information material concerning ADE, ADR or
drug administration.
(5) Semi-standardized and guideline-based single
face-to-face interviews with medical assistants/
receptionists
Interviews will be performed with the medical
assistants to gain information about patients’
frequently asked questions at the reception area of
GPs’ practice. Additionally, we will focus on
medication and related problems. Table 1
summarizes the study measures and their
instruments.
Table 1 Summary of measures
Measure Patient
record
Telephone
interviews with
physicians
Telephone
interviews with
medical assistants
Practice
registration
form
Structure of practice
Sociodemographic data of physicians √
Number of years worked as a physician / medical assistant √ √ √
Type of practice (e.g. single or community practice) √
Patient characteristics
Number of patients quartlerly √
Sociodemographic data of patients √
Percentage of patients older than 65 years √
Diagnosis of patient √
Patients participation in chronic care programs √
Patients number of doctor visits √
Medication
Long-term and acute medication (e.g. dosage and active ingredients) √
Other therapies and interventions as well as their frequency and duration
(e.g. physiotherapy, patient education and rehabilitation)
√
Weighting of influencing factors during medication prescription √
Noncompliance of patients receiving polypharmacy √
Reports of adverse events, interactions or other consequences of
polypharmacy
√ √ √
Describing typical patients, reporting problems with medication √
Taking account of recommendations in the PRISCUS-List √
Organization and processes in practice
Needed time for treating patients receiving polypharmacy √ √
Difficulties on patient admission √
Potential for changing practice organization to improve the treatment of
patients receiving polypharmacy
√ √
Potential and difficulties concerning cooperation with pharmacies √
Use of individual case vignettes in practice √
Evidence of formal qualifications of medical assistants √ √
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The collected data from the analysis of patients’ records
will be documented pseudonymously via a case report
form and transferred to a SPSS data matrix. After a
plausibility check, the data will be analyzed descriptively
(using 95% confidence intervals). Depending on disper-
sion and variance of the data we will use multivariate
models to find predictors for several outcome para-
meters. The qualitative data gained by interviews will be
categorically interpreted and summarized according to
the qualitative content analysis of Mayring [54].
Discussion
To support the goal of improving out-patient health
care management for patients with multimorbidity, the
status quo of care, risk factors for over-, under- andmisuse of health services and the number as well as
characteristics of concerned individuals must be investi-
gated. This study will provide new evidence about the
process of GPs’ decision making regarding the treat-
ment of multimorbid patients.
Information gained by interviewing medical assistants will
describe the process and content of a preliminary talk at the
reception area of GPs’ practice. In case of patient-reported
medication-related problems the medical assistants will
give information about the kind of the problems and
their handling with these issues. Regarding the limited
resources in health care, it is moreover necessary to
reflect existing delegation concepts and to examine their
acceptance by GPs, medical assistants and patients. In
future, it is necessary to analyze the effectiveness and
costs of these concepts.
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study that should be considered. The sample of teaching
practices might be not representative for all GPs in
Saxony [55]. There could be differences in non-teaching
practices regarding prescription and managing treatment
because of more evidence based knowledge based on
regular teaching trainings. Concerning representativeness
of the patient sample of research active GPs compared to
non-active GPs, there are hints that there are no signifi-
cant differences regarding demography, morbidity and
mortality of the patients [56,57]. Despite the likely repre-
sentativeness of our basic population of patients, the data
could be biased by patients’ voluntary participation of the
study (response bias). Furthermore, quality and quan-
tity of patients’ records could differ between GPs. For
example there will be known and unknown patients’
diseases, which will not be coded by the GPs as long-
term diagnosis. Based on this, some patients will not
apply to the inclusion criteria. Consequently, the preva-
lence of chronic conditions and multimorbidity would be
underestimated. Summarized, interpretation of the re-
sults should be done with respect to the context and the
setting. The qualitative parts of our study will help to
detect and to understand similarities and differences in
GPs’ acts.
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